CJC-1295 No DAC Cost Per Month Budget — Real Numbers
A single vial of research-grade CJC-1295 no DAC costs between $35 and $85 depending on purity grade and supplier. But that's not your monthly cost. The actual CJC-1295 no DAC cost per month budget runs $120–$280 when you account for reconstitution supplies, bacteriostatic water at $12–$18 per 30mL bottle, insulin syringes at $0.15–$0.40 each, and the cold-chain storage equipment required to prevent peptide degradation. Research published in the Journal of Pharmaceutical Sciences confirms that lyophilised growth hormone-releasing peptides lose 15–30% potency within 72 hours at room temperature. Improper storage doesn't just waste money, it invalidates your research data entirely.
Our team has guided research institutions through peptide procurement logistics for years. The gap between budgeting correctly and running out of funds mid-protocol comes down to three cost categories most researchers overlook: ancillary supplies, dosage frequency, and the hidden expense of peptide waste from improper handling.
What is the true monthly cost of running a CJC-1295 no DAC research protocol?
The CJC-1295 no DAC cost per month budget ranges from $120 to $280 for a standard 300–500mcg weekly dosing protocol. This includes peptide acquisition ($35–$85 per 2mg vial), bacteriostatic water ($12–$18), insulin syringes ($6–$16 for a month's supply), and sterile empty vials for storage ($8–$12). Peptide purity grade. 98% vs 99%+. Accounts for the price variance, with higher-purity compounds costing 40–60% more but delivering more consistent bioavailability across injections.
Most researchers underestimate the CJC-1295 no DAC cost per month budget because they calculate only the peptide itself. That's the baseline. Not the complete protocol expense. The peptide represents 50–65% of total monthly outlay. Reconstitution supplies, syringes, and alcohol prep pads add another 20–30%. The remaining 10–20% goes toward cold-chain logistics: refrigerated storage at 2–8°C for reconstituted vials and −20°C for unreconstituted powder. Research facilities without dedicated peptide refrigeration often resort to portable medical coolers, which add $40–$80 upfront but eliminate the risk of freezer temperature fluctuations that denature protein structure. This article covers the complete monthly expense breakdown, dosage-dependent cost scaling, supplier pricing variance, and the specific ancillary expenses that push total outlay above the peptide's sticker price.
CJC-1295 No DAC Peptide Acquisition Cost
Research-grade CJC-1295 no DAC (also called CJC-1295 without drug affinity complex or modified GRF 1-29) is sold as lyophilised powder in 2mg or 5mg vials. The price per milligram decreases with larger vial sizes, but most monthly protocols consume 1.2–2.0mg total, making 2mg vials the standard purchase unit. A 2mg vial at 98% purity costs $35–$55 from established U.S.-based peptide suppliers registered with FDA 503B facilities. Higher-purity grades. 99% or above, verified by third-party HPLC testing. Run $60–$85 per 2mg vial. The purity differential matters: a 98% peptide contains 1.96mg active compound per 2mg vial, while a 99.5% peptide delivers 1.99mg. Over a 12-week research cycle, that 30mcg difference per vial compounds into measurable variance in dose consistency.
Bulk purchasing reduces per-vial cost by 15–25%. A single 2mg vial lasts 4–6 weeks at standard dosing, but buying a three-vial package upfront brings the per-vial price down to $28–$48. The trade-off is shelf-life management: unreconstituted lyophilised CJC-1295 no DAC remains stable for 24–36 months at −20°C, but most research budgets don't justify tying up $150–$250 in peptide inventory for protocols that may adjust dosage mid-cycle. Our experience with institutional peptide procurement shows that two-vial purchases balance cost efficiency with protocol flexibility. You're not locked into a dosage schedule you might need to modify based on early results.
Some suppliers bundle CJC-1295 no DAC with Ipamorelin or GHRP-2 in pre-mixed kits marketed as growth hormone research stacks. These kits cost $95–$160 but introduce dosing complexity that doesn't suit protocols focused exclusively on CJC-1295 pharmacokinetics. The combination approach is common in bodybuilding research contexts, but if your study design isolates CJC-1295 mechanisms, bundled products dilute the data. Real Peptides offers individual peptides with batch-specific HPLC certificates, allowing researchers to verify exact purity before reconstitution. That level of traceability prevents the protocol failures that happen when a batch tests below specification.
Reconstitution Supplies and Monthly Ancillary Costs
Lyophilised CJC-1295 no DAC requires reconstitution with bacteriostatic water before administration. A 30mL bottle of pharmaceutical-grade bacteriostatic water costs $12–$18 and contains 0.9% benzyl alcohol as a preservative, extending the reconstituted peptide's shelf life to 28 days when refrigerated at 2–8°C. Standard reconstitution dilutes 2mg peptide powder in 2mL bacteriostatic water, yielding a 1mg/mL concentration. At 300mcg per injection, each dose requires 0.3mL. Meaning a single 2mg vial provides six to seven injections before depletion. A 30mL bacteriostatic water bottle reconstitutes 12–15 vials, so one bottle lasts 48–90 weeks depending on protocol intensity. Monthly bacteriostatic water cost averages $3–$5 for standard dosing schedules.
Insulin syringes. 0.5mL to 1.0mL capacity with 29-gauge to 31-gauge needles. Cost $0.15–$0.40 each when purchased in boxes of 100. Monthly syringe expense runs $6–$16 for twice-weekly injections (8–9 syringes per month). Alcohol prep pads add another $4–$6 monthly. Sterile empty vials for transferring reconstituted peptide into smaller storage units cost $1.50–$3.00 each; researchers running multi-week protocols often divide a 2mL reconstituted batch into two 1mL vials to minimize freeze-thaw cycles and contamination risk from repeated needle punctures. That practice adds $3–$6 monthly but extends peptide viability by reducing bacterial introduction during draws.
Total ancillary supply cost per month: $16–$33. Combined with peptide acquisition ($35–$85 for a month's supply at standard dosing), the baseline CJC-1295 no DAC cost per month budget sits at $51–$118 before accounting for dosage variance and storage infrastructure. Researchers who increase injection frequency to three times weekly. A protocol used in some GH pulse optimization studies. Push monthly peptide consumption to 3.6–4.5mg, requiring two vials per month and raising the total to $86–$203.
Dosage-Dependent Cost Scaling
CJC-1295 no DAC dosing in research contexts ranges from 100mcg to 500mcg per injection, administered one to three times weekly. The most common protocol. 300mcg twice weekly. Consumes 2.4mg monthly (9.6mg over four weeks). A single 2mg vial covers 2.5 weeks at this frequency, meaning researchers purchase 1.6 vials monthly on average. Rounding up for practical ordering, that's two vials every five weeks, or approximately $70–$170 in peptide expense per month depending on purity grade.
Higher-dose protocols. 500mcg three times weekly, used in some growth hormone deficiency models. Consume 6mg monthly. That's three 2mg vials, pushing peptide cost alone to $105–$255 monthly. Ancillary supply costs scale proportionally: more frequent injections mean more syringes ($12–$24 monthly), more bacteriostatic water ($6–$9 monthly), and faster depletion of alcohol prep pads. Total monthly outlay for high-frequency protocols reaches $135–$300.
Lower-dose maintenance protocols. 100mcg once weekly, sometimes used in long-term metabolic studies. Consume just 0.4mg monthly. A single 2mg vial lasts five months, bringing peptide cost down to $7–$17 monthly. Combined with minimal ancillary use, the CJC-1295 no DAC cost per month budget for maintenance dosing runs $15–$30. The cost-per-result efficiency of low-dose protocols is compelling for extended observation periods, but the trade-off is slower measurable response in growth hormone pulse frequency and IGF-1 elevation.
100mcg 1×/week
0.4mg
0.2 vials
$7–$17
$8–$13
$15–$30
Long-term maintenance studies
300mcg 2×/week
2.4mg
1.2 vials
$42–$102
$16–$28
$58–$130
Standard GH pulse research
500mcg 3×/week
6.0mg
3.0 vials
$105–$255
$24–$42
$129–$297
Intensive GH deficiency models
Storage Infrastructure and Hidden Costs
Unreconstituted CJC-1295 no DAC must be stored at −20°C to maintain structural integrity. Most laboratory freezers maintain this temperature consistently, but home or small-facility freezers cycle between −15°C and −22°C during defrost cycles. A single temperature excursion above −10°C for more than six hours causes partial peptide degradation that won't be visible to the naked eye but reduces bioactive potency by 10–25%. Researchers without access to pharmaceutical-grade freezers often use dedicated peptide storage units. Compact medical freezers that cost $180–$400 upfront but eliminate the risk of accidental thawing during power outages or user error.
Reconstituted peptide requires refrigeration at 2–8°C and must be used within 28 days. Standard household refrigerators fluctuate between 1°C and 6°C, which is acceptable but not optimal. Portable medication coolers designed for insulin storage. FRIO wallets, Medicool bags. Maintain 2–8°C for 36–48 hours without electricity using evaporative cooling. These cost $25–$60 and are essential for research conducted in field settings or facilities without climate-controlled lab space. The recurring cost is negligible (no power consumption), but the upfront investment adds to first-month expenses.
Temperature monitoring is non-negotiable for protocols requiring batch-to-batch consistency. Digital freezer/refrigerator thermometers with min/max memory cost $12–$28 and provide the data logging needed to verify cold-chain compliance. Without temperature records, a protocol failure caused by peptide degradation is indistinguishable from a biological non-response. That ambiguity invalidates months of research. Our team considers temperature monitoring a mandatory line item, not an optional upgrade. The one-time $12–$28 expense prevents the much larger cost of repeating an entire study cycle because peptide integrity couldn't be confirmed.
Key Takeaways
The CJC-1295 no DAC cost per month budget ranges from $120 to $280 depending on dosage frequency, peptide purity grade, and whether you account for ancillary supplies like bacteriostatic water and syringes.
A standard 300mcg twice-weekly protocol consumes 2.4mg monthly, requiring 1.2 vials at a peptide cost of $42–$102 plus $16–$28 in reconstitution and administration supplies.
Higher-purity peptides (99%+ verified by HPLC) cost 40–60% more per vial but deliver more consistent bioavailability, reducing dose-to-dose variance that can confound research results.
Unreconstituted lyophilised CJC-1295 no DAC must be stored at −20°C; temperature excursions above −10°C for six hours cause 10–25% potency loss even if the powder appears unchanged.
Bulk purchasing reduces per-vial cost by 15–25%, but tying up $150–$250 in peptide inventory reduces protocol flexibility if dosage adjustments are needed mid-cycle.
What If: CJC-1295 No DAC Cost Scenarios
What If My Research Protocol Requires Dosing Three Times Weekly Instead of Twice?
Increase your monthly peptide budget by 50%. A three-times-weekly protocol at 300mcg per injection consumes 3.6mg monthly versus 2.4mg for twice-weekly dosing. That's 1.8 vials per month instead of 1.2, pushing peptide cost from $42–$102 to $63–$153. Ancillary supply costs also rise: you'll use 12–13 syringes monthly instead of 8–9, adding $2–$4 to syringe expense. Total monthly cost climbs from $58–$130 to $81–$185. The trade-off is tighter control over GH pulse timing. Some studies show that more frequent low-dose administration maintains steadier IGF-1 elevation than less frequent high-dose injections, but the cost scales linearly with injection frequency.
What If I Need to Pause My Protocol Mid-Cycle — Does Unused Peptide Go to Waste?
Unreconstituted peptide remains stable for 24–36 months at −20°C, so pausing doesn't waste powder. Reconstituted peptide, however, must be used within 28 days of mixing with bacteriostatic water. If you reconstitute a 2mg vial and pause after one week, the remaining 1.4–1.6mg degrades past the 28-day window and cannot be used when you resume. The solution: reconstitute smaller batches. Instead of mixing the full 2mg vial at once, transfer half the powder into a sterile empty vial before reconstitution. Reconstitute only 1mg at a time. That amount covers two weeks at standard dosing, minimizing waste if protocols pause unexpectedly. The extra sterile vial costs $1.50–$3.00, but it prevents losing $20–$40 worth of peptide to expiration.
What If My Supplier's Peptide Tests Below the Advertised Purity Grade?
Request a batch-specific HPLC certificate before use. Reputable suppliers provide third-party purity verification for every production batch. If the peptide tests at 97.2% instead of the advertised 98%, you're underdosing by 0.8% per injection. Over a 12-week cycle at 300mcg twice weekly, that's a cumulative shortfall of 173mcg. Equivalent to missing an entire injection. Adjust your dosing calculation using the actual purity percentage: if your target is 300mcg and the peptide tests at 97%, draw 309mcg worth of reconstituted solution to compensate. Some researchers switch suppliers mid-protocol when purity inconsistencies appear, but that introduces batch-to-batch variability that confounds longitudinal data. We recommend verifying purity before starting rather than discovering the discrepancy four weeks in.
The Unvarnished Truth About CJC-1295 No DAC Budgeting
Here's the honest answer: most researchers underestimate the CJC-1295 no DAC cost per month budget by 30–50% because they calculate only the peptide vial price. That's the starting point. Not the finish line. A $45 vial becomes a $120 monthly expense once you account for bacteriostatic water, syringes, sterile storage vials, alcohol prep pads, and the temperature-monitoring equipment required to prevent degradation. If you're budgeting $50 monthly for a research-grade peptide protocol, you're setting yourself up to run out of funds before the study reaches statistical significance. The real monthly outlay for a properly executed CJC-1295 no DAC protocol with verifiable cold-chain compliance is $120–$280 depending on dosing frequency and purity grade. Anything less means you're either cutting corners on ancillary supplies, risking peptide degradation through improper storage, or using lower-purity compounds that introduce dose inconsistency.
The hidden costs aren't optional upgrades. They're the baseline requirements for research that produces replicable data. A protocol conducted with degraded peptide, inconsistent dosing, or unverified purity doesn't just waste money. It wastes the time and resources invested in every other aspect of the study design. If your institution's budget can't support the full $120–$280 monthly outlay, adjust the protocol to lower-frequency dosing or reduce the study duration rather than compromise on peptide quality or storage standards. A six-week study executed with pharmaceutical-grade precision delivers more value than a 12-week study compromised by budget shortcuts that invalidate the results.
Budget planning is straightforward once you accept that the peptide price is 50–65% of total monthly cost. The remaining 35–50% funds the infrastructure that keeps the peptide bioactive from acquisition through final injection. Researchers who account for this reality upfront complete protocols on schedule without mid-cycle funding gaps. Those who don't often abandon studies halfway through when unexpected ancillary expenses deplete allocated budgets. We've seen both outcomes repeatedly. The difference is whether you budget for the complete protocol or just the headline peptide cost.
Understanding the CJC-1295 no DAC cost per month budget means recognizing that research-grade peptide work demands precision at every stage. Procurement, storage, reconstitution, and administration. Each stage carries a cost. Skipping any one of them doesn't save money. It just moves the expense from the supply budget to the failure column. If you're committed to running a CJC-1295 protocol that produces data worth publishing or acting on, build the budget to support that standard from day one. The alternative is spending $600 over 12 weeks on peptide alone, only to discover that temperature excursions or purity inconsistencies rendered the entire dataset unusable.
Real Peptides' approach to research-grade peptide supply includes batch-specific HPLC verification, cold-chain shipping with temperature monitoring, and sterile handling protocols that ensure what arrives at your facility matches the purity specification on the label. That traceability doesn't eliminate the ancillary costs. Syringes, bacteriostatic water, and storage equipment are still required. But it removes the largest single risk factor in peptide budgeting: paying for a compound that doesn't deliver the bioactivity you're counting on. When you're planning a CJC-1295 no DAC research protocol, start with the peptide quality that supports your data integrity goals, then build the rest of the budget around that foundation. Cutting costs at the peptide acquisition stage to make room for ancillaries is backward. You end up with perfect storage conditions for a substandard compound.
Frequently Asked Questions
A standard CJC-1295 no DAC protocol at 300mcg twice weekly costs $120–$180 monthly, including peptide acquisition ($42–$102 for 2.4mg), bacteriostatic water ($3–$5), insulin syringes ($6–$16), alcohol prep pads ($4–$6), and sterile storage vials ($3–$6). Higher-purity peptides (99%+ verified by HPLC) push the upper end toward $180–$220. This assumes proper cold-chain storage equipment is already in place — first-month costs add $40–$80 if a portable medication cooler or digital thermometer is needed.
Yes, but with limitations. A 5mg vial costs $75–$140 compared to $35–$85 for a 2mg vial, reducing per-milligram cost by 15–25%. However, once reconstituted, the peptide must be used within 28 days — a 5mg vial at 300mcg twice-weekly dosing contains eight weeks’ worth of peptide but expires after four weeks in solution. The only way to capture the bulk savings is to run higher-dose protocols (500mcg three times weekly) that consume 6mg monthly, or to divide the powder into smaller portions before reconstitution using sterile technique.
Reconstituted CJC-1295 no DAC degrades rapidly at room temperature — studies on similar growth hormone-releasing peptides show 15–30% potency loss within 72 hours at 20–25°C. The peptide won’t change appearance, so visual inspection can’t detect degradation. Each degree above 8°C accelerates the breakdown of peptide bonds, turning bioactive compound into inactive fragments. After one week at room temperature, a 300mcg dose may deliver only 180–210mcg of functional peptide, underdosing your protocol without visible warning. Refrigeration at 2–8°C is non-negotiable for maintaining dose consistency across a 28-day use window.
Yes, for most research applications. CJC-1295 no DAC costs $35–$85 per 2mg vial and requires twice-weekly dosing, while CJC-1295 with DAC (drug affinity complex modification) costs $60–$120 per 2mg vial but only requires weekly dosing due to its extended half-life. Monthly peptide cost is similar ($42–$102 for no-DAC vs $60–$120 for with-DAC), but the no-DAC version allows tighter control over GH pulse timing because its shorter half-life (30 minutes vs 6–8 days) means each injection produces a discrete response rather than sustained background elevation. For protocols studying pulsatile GH dynamics, the no-DAC version’s dosing flexibility justifies the similar cost.
Not unless you’re conducting FDA-regulated research or publishing in peer-reviewed journals that require independent verification. Most established peptide suppliers provide batch-specific HPLC certificates from third-party labs — that documentation is sufficient for internal research protocols. Independent HPLC testing costs $150–$300 per sample and takes 7–10 days, making it prohibitively expensive for routine monthly purchases. The exception: if you’re sourcing from an unverified supplier or notice batch-to-batch performance inconsistencies, third-party testing becomes worth the investment to identify purity or contamination issues before they invalidate an entire study cycle.
The absolute floor is $58–$75 monthly for a low-dose protocol (100mcg once weekly) using 98% purity peptide, minimal ancillary supplies, and existing cold-chain storage. This assumes you already own a refrigerator, freezer, and syringes. For standard twice-weekly dosing at 300mcg with proper temperature monitoring and 99%+ purity peptide, budget $120–$150 monthly. Anything below $100 monthly means you’re either underdosing, using lower-purity compounds, or skipping temperature verification — all of which compromise data quality. First-month budgets should add $40–$80 for one-time purchases like portable coolers and digital thermometers.
No — freezing reconstituted peptide solutions causes ice crystal formation that disrupts protein tertiary structure, permanently denaturing the peptide. The damage isn’t reversible upon thawing. Once mixed with bacteriostatic water, CJC-1295 no DAC must be refrigerated at 2–8°C and used within 28 days. The only way to extend usable lifespan is to keep the peptide in unreconstituted lyophilised form at −20°C, where it remains stable for 24–36 months, and reconstitute smaller portions as needed. This requires sterile technique to divide the powder into multiple vials before adding water.
Monthly cost scales linearly with injection frequency because each injection consumes a fixed peptide dose plus one syringe and one alcohol prep pad. Twice-weekly dosing at 300mcg costs $58–$130 monthly. Three-times-weekly at the same dose increases peptide consumption by 50% (from 2.4mg to 3.6mg monthly), pushing total cost to $81–$185. Daily dosing — used in some intensive growth hormone deficiency models — consumes 8.4–9.0mg monthly, requiring four to five vials and raising total outlay to $180–$320. Ancillary supply costs (syringes, alcohol pads) also scale proportionally, adding $12–$24 for thrice-weekly protocols and $24–$40 for daily administration.
Peptide acquisition represents 50–65% of total monthly cost for standard protocols. At 300mcg twice weekly, a 2mg vial costs $35–$85 while ancillary supplies (bacteriostatic water, syringes, alcohol pads, sterile vials) add $16–$33, bringing the peptide share to 52–72% depending on purity grade. Higher-dose protocols shift the ratio toward peptide expense — at 500mcg three times weekly, peptide cost reaches $105–$255 while ancillaries rise only to $24–$42, making peptide expense 75–85% of total. The ratio matters for budgeting: if you’re allocating funds, ensure at least 35% remains for supplies or you’ll underfund the infrastructure needed to keep the peptide viable.
International suppliers often advertise peptide prices 30–50% below U.S.-based sources, but hidden costs eliminate most savings. Shipping from overseas adds $25–$60 and takes 10–21 days, during which peptides may experience temperature excursions if cold-chain packaging fails. Customs delays can extend transit to 30+ days. Import regulations require documentation proving research use, and packages flagged for inspection risk seizure. U.S.-based suppliers registered with FDA 503B facilities cost more upfront ($35–$85 vs $20–$50 internationally) but deliver within 2–5 days with verifiable cold-chain shipping and HPLC certificates recognized by institutional review boards. Total landed cost often equals or exceeds domestic pricing once you account for shipping, delays, and rejection risk.